These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29255397)

  • 21. Paraoxonase gene polymorphisms and haplotype analysis in a stroke population.
    Pasdar A; Ross-Adams H; Cumming A; Cheung J; Whalley L; St Clair D; MacLeod MJ
    BMC Med Genet; 2006 Mar; 7():28. PubMed ID: 16551349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids.
    Reddy ST; Wadleigh DJ; Grijalva V; Ng C; Hama S; Gangopadhyay A; Shih DM; Lusis AJ; Navab M; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2001 Apr; 21(4):542-7. PubMed ID: 11304470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2.
    Shamir R; Hartman C; Karry R; Pavlotzky E; Eliakim R; Lachter J; Suissa A; Aviram M
    Free Radic Biol Med; 2005 Aug; 39(3):336-44. PubMed ID: 15993332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protectors or Traitors: The Roles of PON2 and PON3 in Atherosclerosis and Cancer.
    Witte I; Foerstermann U; Devarajan A; Reddy ST; Horke S
    J Lipids; 2012; 2012():342806. PubMed ID: 22666600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection.
    Costa LG; de Laat R; Dao K; Pellacani C; Cole TB; Furlong CE
    Neurotoxicology; 2014 Jul; 43():3-9. PubMed ID: 24012887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress.
    Liu Y; Mackness B; Mackness M
    Free Radic Biol Med; 2008 Sep; 45(6):743-8. PubMed ID: 18585453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paraoxonase-2 and paraoxonase-3: comparison of mRNA expressions in the placentae of unexplained intrauterine growth restricted and noncomplicated pregnancies.
    Dikbas L; Yapca OE; Dikbas N; Gundogdu C
    J Matern Fetal Neonatal Med; 2017 May; 30(10):1200-1206. PubMed ID: 27380314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The paraoxonase gene family and atherosclerosis.
    Ng CJ; Shih DM; Hama SY; Villa N; Navab M; Reddy ST
    Free Radic Biol Med; 2005 Jan; 38(2):153-63. PubMed ID: 15607899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics of paraoxonases: a brief review.
    Draganov DI; La Du BN
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):78-88. PubMed ID: 14579013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development.
    Aviram M; Kaplan M; Rosenblat M; Fuhrman B
    Handb Exp Pharmacol; 2005; (170):263-300. PubMed ID: 16596803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice.
    Shih DM; Xia YR; Wang XP; Wang SS; Bourquard N; Fogelman AM; Lusis AJ; Reddy ST
    Circ Res; 2007 Apr; 100(8):1200-7. PubMed ID: 17379834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of hepatic paraoxonase-1 expression.
    Fuhrman B
    J Lipids; 2012; 2012():684010. PubMed ID: 22548179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paraoxonases function as unique protectors against cardiovascular diseases and diabetes: Updated experimental and clinical data.
    Li YR; Zhu H; Kauffman M; Danelisen I; Misra HP; Ke Y; Jia Z
    Exp Biol Med (Maywood); 2014 Aug; 239(8):899-906. PubMed ID: 24903163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and Intracellular Localization of Paraoxonase 2 in Different Types of Malignancies.
    Shakhparonov MI; Antipova NV; Shender VO; Shnaider PV; Arapidi GP; Pestov NB; Pavlyukov MS
    Acta Naturae; 2018; 10(3):92-99. PubMed ID: 30397533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice.
    Rozenberg O; Rosenblat M; Coleman R; Shih DM; Aviram M
    Free Radic Biol Med; 2003 Mar; 34(6):774-84. PubMed ID: 12633754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights into the role of paraoxonase 2 in human pathophysiology.
    Parween F; Gupta RD
    J Biosci; 2021; 46():. PubMed ID: 34987135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative modeling of PON2 and analysis of its substrate binding interactions using computational methods.
    Barathi S; Charanya M; Muthukumaran S; Angayarkanni N; Umashankar V
    J Ocul Biol Dis Infor; 2010 Jun; 3(2):64-72. PubMed ID: 22319641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention.
    Mackness MI; Durrington PN; Mackness B
    Am J Cardiovasc Drugs; 2004; 4(4):211-7. PubMed ID: 15285696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy.
    Rosenblat M; Hayek T; Hussein K; Aviram M
    Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):175-80. PubMed ID: 14592851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Directed evolution of recombinant serum paraoxonase (PON) variants.
    Aharoni A; Tawfik DS
    Discov Med; 2004 Apr; 4(21):120-4. PubMed ID: 20705007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.